High resolution genotyping of complex immune regions

Scisco Genetics specializes in high-resolution genotyping of complex immune regions, particularly focusing on HLA (human leukocyte antigen) typing and its implications for transplant outcomes and disease associations. The company employs advanced Next Generation Sequencing (NGS) technology, specifically utilizing the Illumina MiSeq platform. This sequencing-by-synthesis approach allows for the amplification and sequencing of DNA samples, resulting in millions of reads that can be analyzed to provide unambiguous HLA allele types and KIR (Killer Cell Immunoglobulin-like Receptor) haplotypes. Scisco Genetics emphasizes the importance of accuracy in their testing, aiming for 100% accuracy in typing when provided with high-quality DNA samples. Their quality assurance program is recognized by the American Society for Histocompatibility and Immunogenetics (ASHI) and the Clinical Laboratory Improvements Amendments (CLIA).

In addition to NGS, Scisco Genetics offers a range of products and services, including Scisco Services™ for HLA and KIR typing, and ScisCloud Software™ for laboratory workflow and data management. The company has developed the Integrated Genotyping System (IGS) to address challenges in adopting NGS in clinical settings, enhancing the precision of genetic analysis. The HLA complex, which is highly polymorphic and critical for immune function, is central to their work, as specific HLA alleles are linked to susceptibility and resistance to various diseases. Scisco Genetics' innovative approaches aim to streamline the genotyping process, reduce costs, and improve the reliability of results, thereby advancing the field of precision medicine.

United States

Scisco Genetics Inc, a Seattle-based spin-off from the Fred Hutchinson Cancer Research Center, is a leading provider of sequencing services and products for genotyping the immune system.

Scisco Genetics

Company Details